Hayden Farquhar

Real-World Reporting Profile of Xanomeline-Trospium (Cobenfy), the First Muscarinic Agonist Antipsychotic: A Disproportionality Analysis of the FDA Adverse Event Reporting System

Preprint version 3.1, corresponding to the second-round revision submitted to Schizophrenia Bulletin. First real-world post-marketing pharmacovigilance analysis of xanomeline-trospium (Cobenfy) in the FDA Adverse Event Reporting System, applying a four-method disproportionality b...